Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

should be classified as a reduction of equity and, accordingly, did not record any reserve charges during the first quarter of 2009. These decreases were partially offset by a $0.1 million increase in professional fees associated with the preparation of the Company's SEC filings.

The Company recorded net interest and other expense of $1.2 million for the first quarter of 2009 compared to net interest and other income of $0.1 million for the first quarter of 2008. The decrease in net interest and other income resulted from an additional impairment in the amount of $0.9 million to the Company's auction rate securities due primarily to their continued illiquidity and a $0.4 million decrease in interest income, due to a decrease in cash and short-term investments during the quarter.

As a result, the Company's net loss for the quarter ended March 31, 2009 was $8.3 million compared to a net loss of $7.8 million for the quarter ended March 31, 2009. The loss for the quarter ended March 31, 2008 includes a loss from discontinued operations of $0.7 million.

As of March 31, 2009, the Company had $25.6 million in cash and investments (including auction rate securities recorded at their fair value) compared to $33.9 million as of December 31, 2008. The decrease of $8.3 million was due to cash spent during the first quarter of $7.4 million and an impairment to the auction rate securities of $0.9 million discussed above. Cash and short-term investments as of March 31, 2009 are net of $2.1 million in cumulative impairment charges recorded for the company's auction rate securities. Based on the amount of cash and short-term investments on hand, the $11.0 million received from the sale of common stock to Cadila on April 1, 2009, the approximately $7.5 million received from sales of common stock under the Wm Smith & Co. sales agreement through May 5, 2009, along with the Company's intention to pay 50% of the balance of its
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... Gain recognition for leadership and ... the biotech industry. Nominations are now being accepted ... you by the Bio Supply Management Alliance ... management professionals for the past 7 years. , ... Biotech industry – Manufacturers, Service Providers, Material Suppliers, ...
(Date:7/24/2014)... , July 24, 2014  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, announced today that ... presentation to investors on Tuesday, July 29, 2014, ... presentation will include an overview of Asterias, business ... webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at least 15 ...
(Date:7/24/2014)... rely on sophisticated equipment, trained personnel, and detection ... against terrorist attacks. A revolutionary new electronic chip ... their job much easier. , The groundbreaking nanotechnology-inspired ... Aviv University ,s School of Chemistry and Center ... Herzliya company Tracense, picks up the scent of ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4Nano-sized chip 'sniffs out' explosives far better than trained dogs 2
... Jessica N Ebright 1 and Catherine Bowes Rickman 1, 2, ... Biology, Duke University Medical Center, Durham, , NC 27710 ... , Duke University Medical Center, Box 3802, Durham, NC ... bowes007@duke.edu , , ...
... Julio E Celis 1 , Morten stergaard 1 , Pamela Celis 1 , Hanne ... 2 , 1 Department of Medical Biochemistry ... University of Aarhus, Aarhus, Denmark , 2 Department ... Bladder cancer comprises a broad spectrum of tumors that includes ...
... Diana Davis, Aiguo Zhang, Jim Torrence, and Emily Dale, Bio-Rad Laboratories,Inc., 2000 Alfred Nobel ... Introduction , ... The concentrations of analytes in these assays ... standard curve. A regression analysis is performed to derive , ...
Cached Biology Technology:Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 2Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 3Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 4Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 5Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 6Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 7Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 2Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 3Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 4Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 5Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 6Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 7Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 8Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 9Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 10Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C 11Selection of Standards for Bio-Plex Cytokine Assays, Rev A 2Selection of Standards for Bio-Plex Cytokine Assays, Rev A 3Selection of Standards for Bio-Plex Cytokine Assays, Rev A 4Selection of Standards for Bio-Plex Cytokine Assays, Rev A 5Selection of Standards for Bio-Plex Cytokine Assays, Rev A 6Selection of Standards for Bio-Plex Cytokine Assays, Rev A 7Selection of Standards for Bio-Plex Cytokine Assays, Rev A 8
(Date:7/25/2014)... Ravi Birla, associate professor of biomedical engineering at ... textbook on tissue engineering and artificial organ development., ... a comprehensive guide to entering into the field ... and professor of biomedical engineering at UH, served ... said that while there are other published books ...
(Date:7/25/2014)... a complex congenital central nervous system disease that ... neural tubes during the embryonic phase. Many patients ... incontinence and neurocognitive retardation. Such problems decrease the ... Researchers at Ankara Physical Medicine and Rehabilitation Education ... in children with SB, using the Pediatric Evaluation ...
(Date:7/25/2014)... The routine use of a molecular testing panel ... performing the correct initial surgery for patients with ... University of Pittsburgh Cancer Institute (UPCI), partner with ... Multidisciplinary Thyroid Center and other diagnostic testing agencies, ... initial surgery by 30 percent, according to the ...
Breaking Biology News(10 mins):University of Houston researcher publishes textbook on tissue engineering 2Test increases odds of correct surgery for thyroid cancer patients 2Test increases odds of correct surgery for thyroid cancer patients 3
... Researchers at Albert Einstein College of Medicine of Yeshiva ... single gene in living cells. In an unprecedented study, published in ... were able to follow, in real time, the process of gene ... molecules of messenger RNA (mRNA) that go on to ...
... A study of DNA rearrangements in roundworm chromosomes may offer ... tumors. A report of the research led by University ... was published in the April 22 online edition of the ... region of repetitive DNA sequence that protects the ends of ...
... Infection Research (HZI) in Braunschweig, Germany have discovered a new, ... cells: In this entry mode, the bacteria exploit the muscle ... cytoplasm. Thus, the strategies Salmonella use to infect ... World Health Organization, the number of Salmonella infections ...
Cached Biology News:Scientists observe single gene activity in living cells 2Study in roundworm chromosomes may offer new clues to tumor genome development 2Salmonella utilize multiple modes of infection 2
ERalpha (Ser 104/106)...
... while maintaining high cell viability , ... , Fast: less than one ... , Highly reproducible results from ... with the Bio-Rad Gene Pulser Xcell System ...
Agarose, pulse field, 250 g. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1800 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Mouse CXCR3 Allophycocyanin MAb (Clone 220803)...
Biology Products: